Lead Compound
According to the American Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. Virtually all cancers are either aggressive at the onset or become aggressive over time. There are two genes which are associated with aggressive forms of cancer: Her2 and Top2. Herceptin®, a drug marketed by Roche, is an effective treatment for Her2 positive patients. There are currently no effective therapies that target Top 2 positive patients. Inhibition of Topoisomerase II activity (Top2) is essential in the fight against aggressive types of cancer, including multi-resistant breast cancer and metastatic cancer.
We have used our proprietary Difluoro-Chemistry to synthesize Adva-27a, an irreversible stoichiometric inhibitor of Topoisomerase II (Top2).
Our published data show that Adva-27a is a true Topoisomerase II inhibitor and is significantly more effective at killing aggressive cancer cells than Etoposide, the current drug of choice.
Unique Features of Adva-27a
- Adva-27a will be the only Topoisomerase II Inhibitor on the Market.
- Adva-27a can be taken orally.
- Adva-27a’s initial indication will be multi-drug resistant breast cancer. Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).
The following is a 3D model of our exciting Adva-27a:
